Back to Awarded Treatment Trials
Awarded Trial: 03T-413
Grant ID
03T-413
Illness
Schizophrenia
Primary Drug/Intervention
L-carnosine
Primary Dosage
up to 2000 mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Chengappa
Sample Size
84
Duration of Study Period for Each Subject
4 months
Outcome Measurements
Cognitive battery, PANSS, CGI, CDS, quality of life scales
Results
In a double-blind trial, 75 patients with schizophrenia were randomized to L-carnosine, 2000 mg/d, for 3 months and assessed on a variety of cognitive tests. Patients on L-carnosine showed significant improvement on some tests of executive function, specifically set shifting and strategic target detection tests.
Publication
Chengappa KNR, Turkin SR, DeSanti S, Bowie CR, Brar JS, Schlicht PJ, Murphy SL, Hetrick ML, Bilder R, Fleet D. A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia. Schizophr Res. 2012 Dec;142(1-3):145-52.
Link
http://www.ncbi.nlm.nih.gov/pubmed/23099060
PI Name
Kadiamada Chengappa
Degree
MD
Center
Western Psychiatric Institute and Clinic
Institution
University of Pittsburgh Medical Center
Address
3811 O'Hara Street
City or Town
Pittsburgh
State or Province
PA
Zip or Postal Code
15213
Country
USA
Email Address
chengappakn@msx.upmc.edu